BioNTech’s Singapore subsidiary, BioNTech Pharmaceuticals Asia Pacific, has signed an agreement with Novartis Singapore Pharmaceutical Manufacturing to obtain a GMP-certified production facility in the country.
The latest progression is part of BioNTech’s expansion plans for its overseas presence in Asia.
With the support of the Singapore Economic Development Board (EDB), the site will be fully operational until the end of next year.
It will serve as BioNTech’s regional headquarters.
With this acquisition, this Singapore plant will be the country’s first messenger ribonucleic acid (mRNA) production facility.
The facility will identify regional production expertise that will expand BioNTech’s portfolio of vaccines and mRNA treatments in Asia Pacific at advertising and clinical scale.
It also has to extend to the manufacture of other categories of drugs such as mobile therapies.
Initially, the site will be ready for the production of applicants for mRNA-based products and legal vaccines and treatments for infectious diseases.
This may come with the company’s Covid-19 vaccine and potential oncology product candidates.
After full construction, the built-in mRNA production facility is expected to have the capacity to produce up to several hundred million doses of mRNA-based vaccines on a year-consistent basis.
By 2024, the facility is expected to generate more than one hundred jobs in the country in fields.
BioNTech’s Chief Operating Officer, Dr. Sierk Poetting, said: “We are excited to take a step towards expanding our global production network in Singapore, supporting the production of mRNA-based vaccines and treatments for the Asia-Pacific region.
“The acquisition gives us the opportunity to boost the status quo of an mRNA production facility and thereby more rapidly develop the capacity for prospective clinical studies and the source of publicity for our vaccines and mRNA-based therapies for the region. “
In February, the company began a multi-objective collaboration with Medigene to expand T-cell receptor-based immunotherapies for cancer.
The cellular and genetic treatment of the pharmaceutical generation is supported by Cytiva.
Editorial content is produced independently and respects journalistic integrity criteria. Thematic sponsors don’t care about creating editorial content.